Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlygic + Neoadjuvant Chemotherapy in TNBC
NCT02779855Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- May 2017
- Primary completion
- Sep 2020
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of talimogene laherparepvec in triple-negative breast cancer (TNBC), sponsored by Moffitt Cancer Center. Started May 2017; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02779855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02779855.